Haemonetics (HAE) Long-Term Deferred Tax (2010 - 2026)

Haemonetics has reported Long-Term Deferred Tax for 17 years, with the latest figure at $9.4 million in Q2 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 20.29% year-over-year to $9.4 million in Q2 2026; TTM through Jun 2026 was $9.4 million, a 20.29% increase from a year earlier, with the FY2026 full-year figure at $9.5 million, up 22.02% from the prior year.
• Long-Term Deferred Tax was $9.4 million for Q2 2026 at Haemonetics, down from $9.5 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $9.5 million in Q1 2026, with the low at $4.3 million in Q4 2022.
• Average Long-Term Deferred Tax over 5 years is $6.7 million, with a median of $7.3 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: Long-Term Deferred Tax slipped 29.39% in 2022, then soared 92.18% in 2024.
• Over 5 years, Long-Term Deferred Tax stood at $4.8 million in 2022, then rose by 4.71% to $5.1 million in 2023, then surged by 57.79% to $8.0 million in 2024, then slipped by 8.39% to $7.3 million in 2025, then increased by 28.72% to $9.4 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $9.4 million (Q2 2026), $9.5 million (Q1 2026), and $7.3 million (Q4 2025), per Business Quant data.